查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1545568

人工胰臟裝置系統的全球市場

Artificial Pancreas Device Systems
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球人工胰臟裝置系統市場將達到 15 億美元

2023年全球人工胰臟裝置系統市場估計為4.59億美元，預計到2030年將達到15億美元，2023-2030年分析期間複合年成長率為18.8%。閾值懸掛設備系統是本報告分析的細分市場之一，預計複合年成長率為 18.8%，到分析期結束時將達到 12 億美元。分析期間，控制目標 (CTT) 系統產業的複合年成長率預計為 19.7%。

美國市場預計將達到1.269億美元，中國預計複合年成長率為17.8%。

預計2023年美國人工胰臟裝置系統市場規模將達1.269億美元。中國作為世界第二大經濟體，預計2023年至2030年複合年成長率為17.8%，到2030年市場規模將達到2.302億美元。其他值得注意的區域市場包括日本和加拿大，預計在分析期間複合年成長率分別為 16.5% 和 15.8%。在歐洲，德國的複合年成長率預計約為 13.6%。

全球人工胰臟設備系統市場 - 主要趨勢與促進因素總結

人工胰臟裝置系統將如何改變糖尿病治療？

人工胰臟裝置系統 (APDS) 已成為糖尿病照護領域的突破性進步，特別是對於需要精確和持續胰島素管理的 1 型糖尿病患者。這些系統透過將連續血糖監測儀 (CGM) 與胰島素幫浦和先進演算法整合來實現胰島素管理流程的自動化，以密切模仿健康胰臟的功能。透過以最少的人工干預將血糖濃度維持在目標範圍內，APDS 顯著減輕了糖尿病管理的負擔，從而改善患者的治療結果並提高生活品質。隨著技術的不斷進步，與傳統的胰島素輸送方法相比，這些系統提供了無與倫比的精確度和控制，被譽為糖尿病治療的未來。

哪些技術創新正在推動人工胰臟系統的成功？

持續的技術創新，特別是感測器的準確性、演算法的複雜性和無縫設備整合，極大地推動了人工胰腺設備系統的成功。 CGM 技術的最新改進已經開發出感測器，可以透過更少的校準提供高精度和可靠的葡萄糖測量，這是 APDS 有效性的一個重要因素。先進的演算法可以預測血糖趨勢並即時自動調整胰島素分泌，使這些系統能夠更好地回應身體的需求。同時管理胰島素和升糖素的雙激素系統的發展代表著在運動、疾病和其他困難情況下增強血糖控制的一個有希望的突破。這些創新不僅提高了 APDS 的有效性，而且使其在日常使用中更容易使用、更舒適。

支持人工胰臟系統推廣的新趨勢是什麼？

許多新趨勢正在推動人工胰臟設備系統的普及，反映出向更個性化和更容易獲得的糖尿病護理的更廣泛轉變。個人化醫療的推動導致了針對個別患者獨特需求的 APDS 的開發，使這些系統更有效、更易於使用。遠端醫療和遠端監控能力的興起也促進了 APDS 的擴散。這些技術允許連續血糖監測和胰島素調整，而無需親自訪問。此外，糖尿病管理設備健康保險覆蓋率的擴大也讓更多人更容易使用 APDS。 1 型糖尿病的盛行率不斷上升，尤其是在年輕人中，進一步推動了對這些系統的需求，將其作為改善長期健康結果並儘量減少與血糖控制不良相關的風險的手段。

推動人工胰臟設備系統市場成長的因素有哪些？

人工胰臟設備系統市場的成長是由塑造糖尿病管理未來的幾個關鍵因素所推動的。全球糖尿病（尤其是第 1 型糖尿病）盛行率不斷上升，迫切需要更準確、更有效的血糖管理解決方案。連續血糖監測、胰島素幫浦和人工智慧驅動演算法的技術進步顯著提高了 APDS 的性能和可靠性，使其對患者和醫療保健提供者都具有吸引力。遠端醫療服務的擴展和穿戴式健康技術的日益普及，透過提供更方便、更有效的糖尿病管理選擇，進一步推動了市場的發展。此外，對兒科糖尿病治療的日益重視正在推動更易於使用、侵入性較小的設備的開發，從而擴大了市場潛力。隨著醫療保健系統繼續優先考慮基於價值的護理，APDS 改善患者治療結果和降低長期糖尿病管理成本的能力預計將進一步推動市場成長。

受訪企業範例（共47家）

  • Beta Bionics, Inc.
  • Bigfoot Biomedical, Inc.
  • Johnson & Johnson
  • Medtronic PLC
  • Pancreum, Inc.
  • Tandem Diabetes Care, Inc.
  • TypeZero Technologies LLC

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP10385

Global Artificial Pancreas Device Systems Market to Reach US$1.5 Billion by 2030

The global market for Artificial Pancreas Device Systems estimated at US$459.0 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.8% over the analysis period 2023-2030. Threshold Suspended Device Systems, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Control-to-Target (CTT) Systems segment is estimated at 19.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$126.9 Million While China is Forecast to Grow at 17.8% CAGR

The Artificial Pancreas Device Systems market in the U.S. is estimated at US$126.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$230.2 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Artificial Pancreas Device Systems Market - Key Trends and Drivers Summarized

How Are Artificial Pancreas Device Systems Transforming Diabetes Care?

Artificial pancreas device systems (APDS) have emerged as a groundbreaking advancement in diabetes care, particularly for those with Type 1 diabetes who require precise and continuous insulin management. These systems automate the process of insulin delivery by integrating continuous glucose monitors (CGMs) with insulin pumps and advanced algorithms, closely mimicking the function of a healthy pancreas. By maintaining glucose levels within a target range with minimal manual intervention, APDS significantly lighten the burden of diabetes management, leading to improved patient outcomes and an enhanced quality of life. As technology continues to advance, these systems are being hailed as the future of diabetes treatment, offering unmatched precision and control compared to traditional insulin administration methods.

What Technological Innovations Are Driving the Success of Artificial Pancreas Systems?

The success of artificial pancreas device systems has been largely driven by continuous technological innovations, particularly in sensor accuracy, algorithm sophistication, and seamless device integration. Recent improvements in CGM technology have resulted in sensors that provide highly accurate and reliable glucose readings with fewer calibrations, a critical component for the effectiveness of APDS. Advanced algorithms capable of predicting glucose trends and automatically adjusting insulin delivery in real-time have made these systems even more responsive to the body’s needs. The development of dual-hormone systems that administer both insulin and glucagon represents a promising leap forward, offering enhanced glucose control during exercise, illness, or other challenging conditions. These innovations have not only improved the efficacy of APDS but also made them more user-friendly and comfortable for everyday use.

What Emerging Trends Are Fueling the Adoption of Artificial Pancreas Systems?

A number of emerging trends are fueling the widespread adoption of artificial pancreas device systems, reflecting a broader shift toward more personalized and accessible diabetes care. The push for personalized medicine has led to the development of APDS tailored to the unique needs of individual patients, making these systems more effective and user-friendly. The rise of telemedicine and remote monitoring capabilities has also contributed to the growing popularity of APDS, as these technologies enable continuous glucose monitoring and insulin adjustments without the need for in-person visits. Additionally, expanded health insurance coverage for diabetes management devices is making APDS more accessible to a wider audience. The increasing prevalence of Type 1 diabetes, especially among younger populations, is further driving the demand for these systems as a means to improve long-term health outcomes and minimize the risks associated with poor glucose control.

Which Factors Are Fueling the Growth of the Artificial Pancreas Device Systems Market?

The growth in the artificial pancreas device systems market is fueled by several key factors that are shaping the future of diabetes management. The rising global prevalence of diabetes, particularly Type 1 diabetes, has created an urgent need for more precise and effective glucose management solutions. Technological advancements in continuous glucose monitoring, insulin pumps, and AI-driven algorithms have significantly improved the performance and reliability of APDS, making them more attractive to both patients and healthcare providers. The expansion of telehealth services and the increasing adoption of wearable health technologies are further boosting the market by providing more convenient and effective diabetes management options. Additionally, the growing emphasis on pediatric diabetes care is driving the development of more user-friendly and less invasive devices, broadening the market’s potential. As healthcare systems continue to prioritize value-based care, the ability of APDS to improve patient outcomes and reduce long-term diabetes management costs is expected to further propel the market’s growth.

Select Competitors (Total 47 Featured) -

  • Beta Bionics, Inc.
  • Bigfoot Biomedical, Inc.
  • Johnson & Johnson
  • Medtronic PLC
  • Pancreum, Inc.
  • Tandem Diabetes Care, Inc.
  • TypeZero Technologies LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Artificial Pancreas Device Systems - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Diabetes Propels Growth in Artificial Pancreas Device Systems Market
    • Advancements in Continuous Glucose Monitoring (CGM) Drives Adoption
    • Integration of Insulin Pumps with Advanced Algorithms Expands Addressable Market Opportunity
    • Regulatory Approvals for Hybrid Closed-Loop Systems Propel Market Expansion
    • Improved Patient Outcomes with Automated Insulin Delivery Systems Spurs Growth
    • Increasing Adoption of Wearable Health Technology Drives Demand for Artificial Pancreas Devices
    • Innovation in Biocompatible Materials and Sensors Generates Opportunities for Enhanced Device Durability
    • Development of Dual-Hormone Systems Throws the Spotlight on Next-Generation Solutions
    • Rising Incidence of Type 1 Diabetes Among Youth Fuels Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Artificial Pancreas Device Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Artificial Pancreas Device Systems Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Threshold Suspended Device Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Threshold Suspended Device Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Control-to-Target (CTT) Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Control-to-Target (CTT) Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Control-to-Range (CTR) Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Control-to-Range (CTR) Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 10: USA Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 11: USA 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • CANADA
    • TABLE 12: Canada Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 13: Canada 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • JAPAN
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 14: Japan Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Japan 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • CHINA
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 16: China Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: China 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • EUROPE
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for Artificial Pancreas Device Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • FRANCE
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 22: France Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: France 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • GERMANY
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 24: Germany Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Germany 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • ITALY
    • TABLE 26: Italy Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Italy 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • UNITED KINGDOM
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 28: UK Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: UK 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of Europe 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Asia-Pacific 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 34: Rest of World Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Rest of World 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030

IV. COMPETITION